Blake Foxworthy,Chen Dai,Elizabeth C. Davis,Ana C. Xavier,Julienne Brackett,David Dickens,Alissa Kahn,Isaac Martinez,Archana Sharma,Carla Schwalm,Jessica Foley,Jennifer Wilkes,Smita Bhatia,Jennifer M. Levine,Emily E. Johnston,Julie A. Wolfson,the POCC Consortium

Abstract:Introduction Children, adolescents, and young adults (CAYAs) with Down syndrome (DS) and hematologic malignancies are particularly vulnerable to infections and related complications. There are limited data regarding COVID‐19 infections in this group. We aimed to understand the clinical course of COVID‐19 in this population. Methods This observational study leverages the de‐identified clinical and sociodemographic data captured by the Pediatric Oncology COVID‐19 Case Report Registry (POCC) regarding CAYAs with cancer and COVID‐19. We evaluated CAYAs (≤21 years at COVID‐19 infection) with hematologic malignancies and COVID‐19 reported from April 1, 2020 to May 2, 2023, comparing those with and without DS. Using multivariable logistic regression, we examined rates of hospitalization, intensive care unit (ICU) admission, respiratory support, and changes in cancer‐directed therapy. Results Among 1408 CAYAs with hematologic malignancies, 55 had DS (CAYA‐DS). CAYA‐DS had higher rates of hospitalization, ICU admission, and respiratory support (p

COVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies